$JAGX News

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Jaguar Health Submits New Animal Drug Application To FDA For Veterinary Medicine For Full Approval Of Crofelemer To Treat Chemotherapy-Induced Diarrhea In Dogs

Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program

Jaguar Health Board Initiates Process To Mull, Review Strategic Options

Jaguar Health Board Initiates Review Of Strategic Alternatives To Maximize Shareholder Value, Aligned With Anticipated NDA Filing For Crofelemer Candidate In Rare Intestinal Failure Diseases

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention

Jaguar Health Announces Data From Preclinical Study Initiates By Magdalena Biosciences Shows Novel Extract Derived From Coca Plant Leaves Stops Weight Gain In Mice

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases

Jaguar Health CEO To Present At Life Sciences Virtual Investor Forum

Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders

Jaguar Health Inc (JAGX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...

Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Prepared Remarks Transcript

Jaguar Health (JAGX) Q3 2025 Earnings Transcript

Jaguar Health Inc (NASDAQ:JAGX) Swings to Profit on Licensing Deal, But Market Sells the News

Jaguar Health Reports First Quarter 2026 Financials

Jaguar Health Q1 EPS $(13.60) Misses $(4.26) Estimate, Sales $20.272M Beat $4.211M Estimate

Jaguar (JAGX) Q4 2025 Earnings Transcript

Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference